Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism.
Gonadotropin-releasing hormone agonists are potent suppressors of ovarian androgen biosynthesis even in the face of severe hyperandrogenism (e.g., hyperinsulinemia, hyperthecosis). Gonadotropin-releasing hormone agonists are clinically useful in the context of hirsutism. The use of Gn-RH-a in the context of hirsutism is not duration-limited in that the induced hypoestrogenism and its consequent complications are likely to be effectively managed by the concurrent provision of estrogen replacement therapy.
Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore.
E Y
EY
Adashi
D000726:Androgen Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000378:metabolism*; D001696:Biomechanical Phenomena; D003276:Contraceptives, Oral / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006628:Hirsutism / Q000503:physiopathology; D006801:Humans; D010049:Ovarian Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010906:Pituitary Hormone-Releasing Hormones / Q000502:physiology*; D011374:Progesterone / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use
D000726:Androgen Antagonists; D000728:Androgens; D003276:Contraceptives, Oral; D004967:Estrogens; D010906:Pituitary Hormone-Releasing Hormones; D013148:Spironolactone; D011374:Progesterone